BioSpace News Archive

Larkspur Biosciences announced that its Chief Executive Officer, Catherine Sabatos-Peyton, PhD, will participate in the following upcoming biotech events, including two events surrounding the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco:.

Phathom Pharmaceuticals, Inc. announced an amendment to its term loan facility from Hercules Capital, Inc., a leader in customized debt financing for companies in life sciences and technology-related markets.

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that the first patient has initiated treatment at the Beverly Hills Cancer Center (BHCC) in the Company’s Deltacel-01 clinical trial.

SELLAS Life Sciences Group, Inc. today announced that the first patients have been enrolled in the 60 mg dose cohort in its ongoing Phase 2a clinical trial of its novel and highly selective CDK9 inhibitor, SLS009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.

ClearNote® Health today announced it has entered into a collaboration with Bayer to evaluate biological mechanisms underlying patient response and resistance to treatments for metastatic hormone-sensitive prostate cancer.

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”) today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma.

AnHeart Therapeutics (“AnHeart”) and Foundation Medicine, Inc., today announced the companies have entered a strategic collaboration for the development and regulatory approval of Foundation Medicine’s tissue-based and liquid-based comprehensive genomic profiling tests, FoundationOne®CDx and FoundationOne®Liquid CDx, as companion diagnostics for AnHeart’s investigational next-generation ROS1 inhibitor, taletrectinib, in the United States.

Monogram Orthopaedics Inc. announced that its live stream product demonstration of features of its commercial robot has been postponed due to management’s international travel schedules.

Ambrx Biopharma, Inc., or Ambrx, announced that the Company will be added to the NASDAQ Biotechnology Index, effective prior to the market open on Monday, December 18, 2023.

Veru Inc. announced the pricing of an underwritten public offering of 45,833,333 shares of its common stock at a price to the public of $0.72 per share.